Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

Related Articles by Review for PubMed (Select 22002477)

1.

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr.

Int J Hematol. 2011 Oct;94(4):321-33. doi: 10.1007/s12185-011-0948-y. Epub 2011 Oct 15. Review.

2.

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Zhou Y, Barlogie B, Shaughnessy JD Jr.

Leukemia. 2009 Nov;23(11):1941-56. doi: 10.1038/leu.2009.160. Epub 2009 Aug 6. Review.

3.

Multiple myeloma.

Harousseau JL, Shaughnessy J Jr, Richardson P.

Hematology Am Soc Hematol Educ Program. 2004:237-56. Review.

4.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

5.

Staging and prognostication of multiple myeloma.

Fonseca R, Monge J, Dimopoulos MA.

Expert Rev Hematol. 2014 Feb;7(1):21-31. doi: 10.1586/17474086.2014.882224. Review.

6.

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

Stewart AK, Fonseca R.

J Clin Oncol. 2005 Sep 10;23(26):6339-44. Review.

PMID:
16155017
7.

The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.

Sawyer JR.

Cancer Genet. 2011 Jan;204(1):3-12. doi: 10.1016/j.cancergencyto.2010.11.002. Review.

PMID:
21356186
8.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
9.

Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.

Landgren O, Morgan GJ.

Clin Cancer Res. 2014 Feb 15;20(4):804-13. doi: 10.1158/1078-0432.CCR-13-2159. Epub 2013 Nov 22. Review.

10.

High-risk multiple myeloma: different definitions, different outcomes?

Paszekova H, Kryukov F, Kubiczkova L, Hajek R, Sevcikova S.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):24-30. doi: 10.1016/j.clml.2013.09.004. Epub 2013 Sep 28. Review.

PMID:
24225331
11.

Update on risk stratification and treatment of newly diagnosed multiple myeloma.

Kapoor P, Rajkumar SV.

Int J Hematol. 2011 Oct;94(4):310-20. doi: 10.1007/s12185-011-0947-z. Epub 2011 Oct 18. Review.

PMID:
22005834
12.

Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?

Tassone P, Tagliaferri P, Rossi M, Gaspari M, Terracciano R, Venuta S.

Eur J Cancer. 2006 Jul;42(11):1530-8. Epub 2006 Jul 3. Review.

PMID:
16820292
13.

Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.

Agnelli L, Tassone P, Neri A.

Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S55-68. doi: 10.1517/14712598.2013.793305. Epub 2013 Apr 24. Review.

PMID:
23614397
14.

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2.

Blood. 2011 May 5;117(18):4696-700. doi: 10.1182/blood-2010-10-300970. Epub 2011 Feb 3.

15.

Many multiple myelomas: making more of the molecular mayhem.

Chesi M, Bergsagel PL.

Hematology Am Soc Hematol Educ Program. 2011;2011:344-53. doi: 10.1182/asheducation-2011.1.344. Review.

16.

Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.

Rajkumar SV, Buadi F.

Best Pract Res Clin Haematol. 2007 Dec;20(4):665-80. Review.

PMID:
18070712
17.

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic.

Mayo Clin Proc. 2013 Apr;88(4):360-76. doi: 10.1016/j.mayocp.2013.01.019. Erratum in: Mayo Clin Proc. 2013 Jul;88(7):777. Stewart, Keith [corrected to Stewart, A Keith].

PMID:
23541011
18.

Gene expression profiling and multiple myeloma.

Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK.

Best Pract Res Clin Haematol. 2005;18(4):537-52. Review.

PMID:
16026736
19.

Individualizing therapy using molecular markers in multiple myeloma.

Bergsagel PL.

Clin Lymphoma Myeloma. 2007 Apr;7 Suppl 4:S170-4. Review.

PMID:
17562256
20.

Treatment of myeloma.

Smith ML, Newland AC.

QJM. 1999 Jan;92(1):11-4. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk